GENINCODE PLC — Director's Dealing 2026

May 7, 2026

National Storage Mechanism | Additional information

RNS Number : 3194D

GENinCode PLC

07 May 2026

7 May 2026

GENinCode Plc

("GENinCode" or the "Company")

Grant of Share Options, Surrender of Existing Options & PDMR Dealings

GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that the Company has approved the grant of options over an aggregate of 83,847,292 new ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the 2021 Share Option Plan ('2021 Share Option Plan') to certain directors and employees of the Company (the "New Options"), representing 11.13 per cent. of the Company's existing issued share capital.

Background to the New Options grants

The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The New Options replace 29,856,434 current options ("Existing Options") held by existing option holders, which will be surrendered, and are new grants to those employees who have more recently joined the Group.

Terms of the New Options

The New Options have an exercise price of 1 pence per share and are exercisable on the second anniversary of the date of grant. The New Options will vest over a 24 month period and have a 10-year term.

Surrender of Existing Options

In March 2025, the Company granted options to acquire shares in the capital of the Company to certain employees and directors of the Company pursuant to the 2021 Share Option Plan. These options were granted with an exercise price of 3.7 pence per share.

For directors and employees the existing options will be surrendered for no consideration (the "Option Surrender"), details for which are outlined below. The board believe it is appropriate to issue new share options in replacement of the existing ones to reflect the Company's current share price and to properly incentivise its employees, including its management.

Details of resultant holdings

Following the New Options grant and the Option Surrender, details of options held by Directors, PDMRs and other employees of the Company, are as follows:

Director's name	Position	Number of options surrendered	Number of New Options granted at 1 pence	Aggregate number of options post grant	Current total beneficial holding of Ordinary Shares	Current holding as a % of Issued share capital
Matthew Walls	CEO	5,254,832	30,428,453	30,428,453	14,235,473	1.89%
Paul Foulger	CFO	4,790,062	13,523,757	13,523,757	2,773,587	0.37%
Jordi Puig	COO	3,161,274	21,976,105	21,976,105	15,237,636	2.02%
William Rhodes	Non-Executive Chair	1,197,516	1,267,852	1,267,852	-	0.00%
Huon Gray	Non-Executive Director	837,423	1,267,852	1,267,852	1,905,405	0.25%
Felix Frueh	Non-Executive Director	837,423	845,235	845,235	600,000	0.08%
Sergio Olivero	Non-Executive Director	172,188	2,535,704	2,535,704	24,917,243	3.31%
Other Employees		13,605,716	12,002,334	14,078,585	N/A	N/A
Total:		29,856,434	83,847,292	85,923,543	58,395,757	7.75%

Directors and employees of the Group surrendered Options over an aggregate of 29,856,434 Ordinary Shares. The grant of 71,844,958 New Options exercisable at 1 pence to Matthew Walls, Paul Foulger, Jordi Puig, William Rhodes, Huon Gray, Sergio Olivero, and Felix Frueh are intended to replace their surrendered Options.

Following the grant of the New Options and the Options Surrender, there are Options over a total of 85,923,543 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.41% of the Company's existing issued share capital. 

For more information visit www.genincode.com

Enquiries:

GENinCode Plc	www.genincode.com  or via Walbrook PR
Matthew Walls, CEO
Cavendish Capital Markets Limited	Tel: +44 (0) 20 7220 0500
Giles Balleny / Trisyia Jamaludin (Corporate Finance) Nigel Birks (Specialist Sales) Harriet Ward (Corporate Broking)
Walbrook PR Limited	Tel: 020 7933 8780 or
Anna Dunphy	[email protected]

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.

The notification set out below is provided in accordance with the requirements of MAR.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name			1.     Matthew Walls 2.     Paul Foulger 3.     Jordi Puig 4.     William Rhodes 5.     Huon Gray 6.     Felix Frueh 7.     Sergio Olivero
2	Reason for notification
a.	Position/Status			1.     Chief Executive Officer 2.     Chief Financial Officer 3.     Chief Operating Officer 4.     Non-Executive Chair 5.     Non-Executive Director  6.     Non-Executive Director  7.     Non-Executive Director
b.	Initial notification/ Amendment			Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name			GENinCode Plc
b.	LEI			213800UX6TE7K65O2892
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code			Options over Ordinary Shares of 1p each N/A
b.	Nature of the transaction			Grant of options under the 2021 Share Option Plan with time vesting conditions attached
c.	Price(s) and volume(s)					Exercise Price(s)
	1.	1 pence		30,428,453
2.	1 pence		13,523,757
	3.	1 pence		21,976,105
	4.	1 pence		1,267,852
	5.	1 pence		1,267,852
	6.	1 pence		845,235
	7.	1 pence		2,535,704
d.	Aggregated information - Aggregated Volume - Price			See above
e.	Date of the transaction			6 May 2026
f.	Place of the transaction			Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUNVWRNSUVRAR